INMB: מחיר למכירות INmune Bio Inc

Global isolation of countries is hindering international testing of new drugs, which underscores the significance of the price-to-sales multiple. The value of 767.40 aligns with the current metric, capturing market expectations. However, sanctions and overseas patent complexities create risks for INmune Bio, Inc. (INMB). Meanwhile, colossal demand for Alzheimer's therapy opens vast growth prospects for the developer of selective inhibitors.

P/S reflects the ratio of market capitalization to gross revenue, determining the cost per unit of revenue. Analyzing P/S volatility allows an investor to identify asset overbought conditions or the risk of capital freeze through historical context. This indicator is critical for assessing resource efficiency. For INmune Bio, Inc. (INMB), it reflects market expectations for future licensing deals with Big Pharma in the absence of current M&A strategies.